Leave Your Message
ADT1497-Pembrolizumab Biosimilar-Anti-PDCD1/PD1/CD279 mAb-Research Grade
Hot

ADT1497-Pembrolizumab Biosimilar-Anti-PDCD1/PD1/CD279 mAb-Research Grade

  • Catalog Number ADT1497
  • Host CHO Cells
  • Species Human
  • Target PDCD1/PD-1/CD279
  • Application Elisa, WB

PDCD1 (Programmed Cell Death 1) is a protein-coding gene. Diseases associated with PDCD1 include Systemic Lupus Erythematosus 2 and Multiple Sclerosis. Among its related pathways are Infectious disease and SARS-CoV-2 Infection. Gene Ontology (GO) annotations related to this gene include obsolete signal transducer activity. Inhibitory receptor on antigen-activated T-cells that plays a critical role in induction and maintenance of immune tolerance to self.Delivers inhibitory signals upon binding to ligands CD274/PDCD1L1 and CD273/PDCD1LG2.Following T-cell receptor (TCR) engagement, PDCD1 associates with CD3-TCR in the immunological synapse and directly inhibits T-cell activation (By similarity).

We test for a wide range of parameters, including potency, stability, and safety, so you can trust that our biosimilar antibodies will perform reliably in your research.

Products Categories
Featured Products
recommended service
quick links
Contact Us

Product Background

PDCD1 transmits inhibitory signals when binding to ligands CD274/PCDD1L1 and CD273/PCDD1LG2. After the involvement of T cell receptors (TCR), PDCD1 binds to CD3-TCR in the immune synapse, directly inhibiting T cell activation (through similarity). Inhibition of T cell activation through recruitment of PTPN11/SHP-2: After ligand binding, PDCD1 is phosphorylated within the ITSM motif, leading to recruitment of tyrosine phosphatase PTPN11/SHP-2, which mediates the dephosphorylation of key TCR proximal signaling molecules such as ZAP70, PRKCQ/PKCtheta, and CD247/CD3zeta.

Product Specification

Catalog Number

ADT1497

Product Name

ADT1497-Pembrolizumab Biosimilar-Anti-PDCD1/PD1/CD279 mAb-Research Grade

Alias

MK-3475

Isotype

IgG4 Kappa

Clonity

Monoclonal

Alternate Names

anti-mouse pd-1 antibody, anti-pd-1 antibody, anti pd-1 therapy, anti pd-1 antibody, recombinant pd-1, pd-1 antibody, anti-pd-1 monoclonal antibody, CD279 antibody, anti CD279, anti-CD279 antibody, human CD279 antibody, recombinant CD279, CD279 recombinant antibody, CD279 blocking antibody

Official Symbol

PDCD1/PD-1/CD279

Species

Human

Expression Host

CHO Cells

Reactivity

Human

CAS Number

1374853-91-4

Chemical Formula

C6504H10004N1716O2036S46

Molecular Weight

146.27 KDa

Product Description

Pembrolizumab, as an IgG4 subclass antibody, is preferred over other subclasses as it only induces weakly the complement and cell activation due to low affinity to C1q and Fc receptors. It binds with high affinity to the cell surface receptor programmed cell death protein 1  and it antagonizes its interaction with its known ligands PD-L1 and PD-L2. In normal circumstances, the binding of the ligands of PD-1 to the receptor Inhibitionits the TCR-mediated T cell proliferation and cytokine production. This Inhibitionitory signal seems to be essential for self-tolerance, collateral damage minimizing after immune response against a pathogen and maternal tolerance to fetal tissue. Therefore, the binding of pembrolizumab to PD-1 prevents the Inhibitionitory pathway causing a physiological shift to immune reactivity and enhancing tumor immunosurveillance and anti-tumor immune response.

Mechanism of Action

Pembrolizumab is a monoclonal antibody that targets programmed cell death-1 (PD-1) receptor on T-cells.

Metabolism

Pembrolizumab is catalyzed into small peptides and single amino acids via general protein degradation but it does not rely on metabolism for clearance.

Gene ID

5133

Size

100ug,1mg,5mg

Research Area

Cancer

Application

Elisa, WB

Purity

>95% as determined by SDS-PAGE

Concentration

Batch dependent

Buffer

Supplied in PBS, PH7.5

Storage

Store at -20 °C for 12 months. Store at -80 °C for long term storage.

Shipping Condition

Shipped on ice packs.

Note

This product is for research use only. 

Reference

1. Ma Y, et al. Zhonghua Yu Fang Yi Xue Za Zhi, 2023 Jun 6. PMID 37357205
2. Mirsharif ES, et al. Int Immunopharmacol, 2023 Jun. PMID 37172423
3. Tarique M, et al. Front Immunol, 2023. PMID 37153623

 

FAQ

Leave Your Message